Person:
Lee, Jung Eun

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Lee

First Name

Jung Eun

Name

Lee, Jung Eun
Author's Publications: search.filters.isAuthorOfPublication.1cdbcab0-7953-4565-816f-0b99e9a36073

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    A prospective study of oral contraceptive use and colorectal adenomas
    (Springer Nature, 2016) Charlton, Brittany; Giovannucci, Edward; Fuchs, Charles; Chan, Andrew; Lee, Jung Eun; Cao, Yin; Missmer, Stacey; Rosner, Bernard; Hankinson, Susan; Willett, Walter; Wu, Kana; Michels, Karin
    Purpose—The influence of reproductive factors on colorectal cancer, including oral contraceptive (OC) use, has been examined, but less research is available on OC use and adenomas. Methods—Participants of the Nurses' Health Study who had a lower bowel endoscopy between 1986 (when endoscopies were first assessed) through 2008 where included in this study. Multivariable logistic regression models for clustered data were used to estimate odds ratios and 95% confidence intervals [OR (95% CIs)]. Results—Among 73,058 participants, 51% (N=37,382) reported ever using OCs. Ever OC use was associated with a slight increase of non-advanced adenomas [OR=1.11 95% CI (1.02, 1.21)] but not with any other endpoints. Duration of OC use was not associated with adenomas, but longer times since last OC use were associated with increased odds of adenomas [e.g., compared to never use, 15+ years since last use: OR=1.17 (1.07, 1.27)]. Shorter times since last OC use were inversely associated [e.g., ≤4 years since last use: OR=0.74 (0.65, 0.84)]. Conclusions—We observed a modest borderline increase in risk of colorectal adenomas with any prior OC use. Additionally, more recent OC use may decrease risk while exposure in the distant past may modestly increase risk of adenomas.
  • Thumbnail Image
    Publication
    Risk of ESRD and All Cause Mortality in Type 2 Diabetes According to Circulating Levels of FGF-23 and TNFR1
    (Public Library of Science, 2013) Lee, Jung Eun; Gohda, Tomohito; Walker, William H.; Skupien, Jan; Smiles, Adam M.; Holak, Rita R.; Jeong, Jackson; McDonnell, Kevin P.; Krolewski, Andrzej; Niewczas, Monika
    Introduction: Recent studies demonstrated that circulating fibroblast growth factor (FGF)-23 was associated with risk of end stage renal disease (ESRD) and mortality. This study aims to examine whether the predictive effect of FGF-23 is independent from circulating levels of tumor necrosis factor receptor 1 (TNFR1), a strong predictor of ESRD in Type 2 diabetes (T2D). Methods: We studied 380 patients with T2D who were followed for 8–12 years and were used previously to examine the effect of TNFR1. Baseline plasma FGF-23 was measured by immunoassay. Results: During follow-up, 48 patients (13%) developed ESRD and 83 patients (22%) died without ESRD. In a univariate analysis, baseline circulating levels of FGF-23 and TNFR1 were significantly higher in subjects who subsequently developed ESRD or died without ESRD than in those who remained alive. In a Cox proportional hazard model, baseline concentration of FGF-23 was associated with increased risk of ESRD, however its effect was no longer significant after controlling for TNFR1 and other clinical characteristics (HR 1.3, p = 0.15). The strong effect of circulating level of TNFR1 on risk of ESRD was not changed by including circulating levels of FGF-23 (HR 8.7, p<0.001). In the Cox multivariate model, circulating levels of FGF-23 remained a significant independent predictor of all-cause mortality unrelated to ESRD (HR 1.5, p<0.001). Conclusions: We demonstrated that the effect of circulating levels of FGF-23 on the risk of ESRD is accounted for by circulating levels of TNFR1. We confirmed that circulating levels of FGF-23 have an independent effect on all-cause mortality in T2D.